After @ weeks , very high-risk subjects maintained significantly greater achievement of LDL-C < @ mmol/L ( @ % vs. @ % ) , non-HDL-C < @ mmol/L ( @ % vs. @ % ) and Apo B < @ g/L ( @ % vs. @ % ) single targets and dual/triple targets with atorvastatin @ mg plus ezetimibe vs. atorvastatin @ mg , while attainment of European target for high-risk subjects was generally similar for both treatments .